Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Purchased by Norden Group LLC

Norden Group LLC grew its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 14,465 shares of the company’s stock after acquiring an additional 700 shares during the period. Norden Group LLC’s holdings in Prestige Consumer Healthcare were worth $1,130,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Boston Trust Walden Corp boosted its holdings in shares of Prestige Consumer Healthcare by 43.5% in the fourth quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock worth $64,942,000 after buying an additional 252,089 shares during the period. Wellington Management Group LLP bought a new position in Prestige Consumer Healthcare during the third quarter valued at about $6,342,000. Barclays PLC lifted its holdings in Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after purchasing an additional 71,730 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Prestige Consumer Healthcare in the 3rd quarter valued at $3,947,000. Finally, Geode Capital Management LLC grew its position in shares of Prestige Consumer Healthcare by 4.0% in the third quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on PBH shares. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. DA Davidson lifted their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $92.60.

Prestige Consumer Healthcare Stock Performance

PBH opened at $84.61 on Monday. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The business has a 50 day moving average of $80.04 and a 200-day moving average of $77.28. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $88.36. The stock has a market cap of $4.19 billion, a price-to-earnings ratio of 19.81, a PEG ratio of 2.69 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.